Exchange: NASDAQ·Updated 07:51 PM EDT
Upcoming Earnings: Q2 '26

Reports: Aug 12Pre-Market

Estimated EPS

-$0.10

Estimated Rev

$1.12M

$HUMA Q1 '26 Earnings Results & Recap Humacyte reduced its expected spending by $14.3M for the remainder of 2026 and reorganized its team, resulting in a reduction of total headcount by approximately 25% to focus resources on commercialization.

Generated by Stocktwits using AI and company-reported earnings data for Q2 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.

Historical Earnings

Quarterly

Annual

EPS

Revenue

Fiscal PeriodEstimatedReportedSurpriseResult
Q2 '26
-$0.10
--
--
N/A
Q1 '26
-$0.12
-$0.09
22.20%
BEAT
Q4 '25
-$0.13
-$0.13
3.60%
BEAT
Q3 '25
-$0.15
-$0.11
27.17%
BEAT
Q2 '25
-$0.16
-$0.24
-48.35%
MISSED

Advertisement|Remove ads.